vector icon vector icon
Back
Message sent successfully
fugure icon fugure icon
Back to News & Events

ArtiFascia Pivotal NEOART study has been initiated

linkedin email
ArtiFascia Pivotal NEOART study has been initiated

Nurami has announced the initiation of NEOART clinical study to test its Dural repair patch – ArtiFascia®. Multiple leading EU medical centers participate in the study. The enrollment of patients is ongoing.

Related content
Thursday, 07 Mar 2024
New article published on ArtiFascia: Neural tissue tolerance to synthetic dural mater graft implantation – read more!
Friday, 16 Feb 2024
First ArtiFascia Dura repair procedures carried out in the US
figure icon

Most popular

New article published on ArtiFascia: Neural tissue tolerance to synthetic dural mater graft implantation – read more!
Thursday, 07 Mar 2024
New article published on ArtiFascia: Neural tissue tolerance to synthetic dural mater graft implantation – read more!
First ArtiFascia Dura repair procedures carried out in the US
Friday, 16 Feb 2024
First ArtiFascia Dura repair procedures carried out in the US
Iron Nation invests in Nurami Medical
Thursday, 25 Jan 2024
Iron Nation invests in Nurami Medical
ArtiFascia® Receives 510K Clearance
Thursday, 10 Aug 2023
ArtiFascia® Receives 510K Clearance

Contact us

Israel
USA
Nurami Medical Ltd. HQ
Israel
Nurami Medical Ltd. HQ
36 Ha-Namal St., Haifa, Israel
Nurami Medical INC.
USA
Nurami Medical Inc.
2436 Emrick Boulevard,
Bethlehem, PA 18020, USA
Message sent successfully
Skip to content